LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis
This study identifies LINC01559 as a novel ceRNA that drives osimertinib resistance in lung adenocarcinoma by sponging miR-320a to enhance IGF2BP3 expression. Targeting the LINC01559/miR-320a/IGF2BP3 axis may provide a therapeutic strategy to overcome osimertinib resistance.
Authors
- Leidi Xu
- Ning Chang
- Ying Zhou (ORCID: https://orcid.org/0000-0001-6338-1486)
- L. Xing
- Hangtian Xi
- Jian Zhang (ORCID: https://orcid.org/0000-0001-7217-0111)
- Yibo Zhang (ORCID: https://orcid.org/0000-0002-3502-9933)
- X Xu (ORCID: https://orcid.org/0009-0009-1772-9803)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.3389/fphar.2025.1592846
- Citations
- 3
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China